Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO)
Strategic Profile
Selvita develops dynamically, combining organic growth with acquisitions to deliver research solutions to partners globally. The drug development segment has grown to represent approximately 25% of revenue with 200 employees following the Pozlab acquisition, expanded services including therapeutic antibody discovery and development.
Cyborg Score Rationale
Q1-Q3 2025 generated EUR 63.9 million in commercial revenues (12% y/y increase) and EUR 11.1 million in EBITDA (34% y/y increase). The backlog for 2025 stands at EUR 51 million, reflecting an 11% y/y increase. Strategic positioning with diversified service offerings and growing big pharma relationships provides solid fundamentals.
Top Insights
Big pharma customer revenues reached EUR 20.2 million (51% y/y increase) and now represent 26% of revenue, reinforcing foundation with long-term contracts.
Internal optimization initiatives expected to deliver EUR 6.4 million annual savings in 2026, with first effects visible in H2 2025 strengthening operating profit by EUR 0.5 million.
H2 2024 significantly outperformed H1 with commercial revenues up 20% and EBITDA increasing 86%, signaling strong market recovery.
The company operates with over 950 employees across state-of-the-art labs in Poland and Croatia, with strategic offices in the U.K. and U.S.
Named Competitors
Drug Discovery & CDMO Services — European drug discovery and development CRO with integrated services
Contract Research Services — Global preclinical and analytical research services
Preclinical Drug Discovery — Medicinal chemistry and drug discovery services
Recent Developments
(March 2025) 2024 full-year results show 11% backlog growth for 2025 and rebounding profitability in H2 2024 with 86% EBITDA growth
(December 2024) Hired Dr. Paul Overton as Chief Commercial Officer with 25+ years pharmaceutical/CRO industry experience
(May 2024) Completed acquisition of PozLab, a CDMO expanding drug development capabilities and GMP manufacturing
(March 2024) Launched biologic drug discovery services with therapeutic antibody development capabilities in Wroclaw
Open the full interactive Selvita S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.